Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line
Open Access
|Dec 2013References
- 1. W. A. Denny, Emerging DNA topisomerase inhibitors as anticancer drugs, Expert Opin. Emerg. Drugs
9 (2004) 105-133; DOI: 10.1517/eoed.9.1.105.32948. - 2. L. F. Liu, DNA topoisomerase poisons as antitumor drugs, Annu. Rev. Biochem.
58 (1989) 351-375; DOI: 10.1146/annurev.bi.58.070189.002031. - 3. G. Takemura and H. Fujiwara, Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management, Prog. Cardiovasc. Dis.
49 (2007) 330-352; DOI: 10.1016/j.pcad.2006.10.002. - 4. S. Hitchcock-Bryan, R. Gelber, J. R. Cassady and S. E. Sallan, The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia, Med. Pediatr. Oncol.
14 (1986) 211-215; DOI: http://dx.doi.org/10.1002/mpo.2950140405. - 5. T. Feridooni, A. Hotchkiss, S. Remley-Carr, Y. Saga and K. B. S. Pasumarthi, Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes, PLoS ONE
6 (2011) e22801; DOI:10.1371/journal.pone.0022801. - 6. X. Z. Han, S. Gao, Y. N. Cheng, Y. Z. Sun, W. Liu, L. L. Tang and D. M. Ren, Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes, Biosci. Trends
6 (2012) 19-25; DOI: 10.5582/bst.2012.v6.1.19. - 7. B. Glimelius, Benefit-risk assessment of irinotecan in advanced colorectal cancer, Drug Saf.
28 (2005) 417-433; DOI: http://dx.doi.org/10.2165/00002018-200528050-00005. - 8. J. Weekes, A. K.-Y. Lam, S. Sebesan and Y.-H. Ho, Irinotecan therapy and molecular targets in colorectal cancer: a systemic review, World J. Gastroenterol.
15 (2009) 3597-3602; DOI: http://dx.doi.org/10.3748/wjg.15.3597. - 9. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo and L. Gianni, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev.
56 (2004) 185-229; DOI: 10.1124/pr.56.2.6. - 10. R. Nithipongvanitch, W. Ittarat, M. P. Cole, J. Tangpong, D. K. S. Clair and T. D. Oberley, Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)?, Antioxid. Redox Signal.
9 (2007) 1001-1008; DOI:10.1089/ars.2007.1632. - 11. E. H. Herman and V. J. Ferrans, Amelioration of chronic anthracycline cardiotoxicity by ICRF- -187 and other compounds, Cancer Treat Rev.
14 (1987) 225-259; DOI: 10.1016/0305-7372(87) 90011-9. - 12. S. M. Swain, F. S. Whaley, M. C. Gerber, M. S. Ewer, J. R. Bianchine and R. A. Gams, Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy, J. Clin. Oncol.
15 (1997) 13331340. - 13. S. M. Swain and P. Vici, The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review, J. Cancer Res. Clin. Oncol.
130 (2004) 1-7; DOI: 10. 1007/s00432-003-0498-7. - 14. M. S. Wolin, Interactions of oxidants with vascular signaling systems, Arterioscl. Throm. Vas.Biol.
20 (2000) 1430-1442; DOI: 10.1161/01.ATV.20.6.1430. - 15. D. B. Sawyer, R. Fukazawa, M. A. Arstall and R. A. Kelly, Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane, Circ. Res.
84 (1999) 257-65; DOI: 10.1161/01.RES.84.3.257. - 16. J. Bierau, R. Leen, A. H. van Gennip, H. N. Caron and A. B. P. van Kuilenburg, Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed- phase high performance liquid chromatography; Identification of a novel metabolite of 2-chlorodeoxyadenosine, J. Chromatogr. B
805 (2004) 339-346; DOI: 10.1016/j.jchromb.2004.03.036. - 17. B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y. Boucher and R. K. Jain, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors, Proc. Natl. Acad. Sci. USA
108 (2011) 2909-2914; DOI: 10.1073/pnas.1018892108. - 18. C. E. Runyan, H. W. Schnaper and A.-C. Poncelet, The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells, J. Biol. Chem.
280 (2005) 8300-8308; DOI: 10.1074/jbc.M407939200. - 19. K. Tamaki, S. Okuda, T. Ando, T. Iwamoto, M. Nakayama and M. Fujishima, TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy, Kidney Int.
45 (1994) 525-536.
Language: English
Page range: 493 - 503
Published on: Dec 31, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2013 Tiam Feridooni, Chris Mac Donald, Di Shao, Pollen Yeung, Remigius U. Agu, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.